Newsroom

Sorted by: Latest

-

GigaDevice lance la gamme GD32H7 de microcontrôleurs haute performance de nouvelle génération, destinée à à un large éventail d'applications industrielles

MUNICH--(BUSINESS WIRE)--GigaDevice, une entreprise de premier plan dans le secteur des semi-conducteurs, spécialisée dans les mémoires Flash, les microcontrôleurs 32 bits (MCU), les capteurs et les produits analogiques , lance officiellement sa gamme de microcontrôleurs GD32H7 de nouvelle génération, reposant sur une architecture de puce unifiée. Développée à partir d’une même puce en silicium, avec une configuration IP personnalisée, une optimisation des périphériques et un réglage adapté à c...
-

GigaDevice bringt das GD32H7-Portfolio der neuen Generation mit Hochleistungs-MCUs für industrielle Anwendungen in allen Anwendungsbereichen auf den Markt

MÜNCHEN--(BUSINESS WIRE)--GigaDevice, ein führendes Halbleiterunternehmen, das sich auf Flash-Speicher, 32-Bit-Mikrocontroller (MCUs), Sensoren und analoge Produkte spezialisiert hat, bringt offiziell sein GD32H7-MCU-Portfolio der neuen Generation auf den Markt, das auf einer einheitlichen Chiparchitektur basiert. Die umfassende Produktpalette wurde auf Basis eines einheitlichen Silizium-Chips mit maßgeschneiderter IP-Konfiguration, optimierten Peripheriegeräten und szenariospezifischer Feinabs...
-

Laverock Therapeutics Appoints Parker Moss as Chief Executive Officer and Paul J. Sekhri as Executive Chairman

LONDON--(BUSINESS WIRE)--Laverock Therapeutics (‘Laverock’), a biotechnology company developing disease-responsive advanced therapies through its programmable gene control technology, today announced the appointment of Parker Moss as Chief Executive Officer and member of the Board of Directors, and Paul J. Sekhri as Executive Chairman. Together they will lead Laverock through its transition into a clinical-stage company, including a Series A financing planned for 2027. Parker Moss is a life sci...
-

Plural sammelt 1 Mrd. € ein: Kapital für Tech-Pionier:innen, die ein neues Europa gestalten

London, Tallinn und Paris--(BUSINESS WIRE)--Plural, ein von Gründer:innen und erfahrenen operativen Führungskräften geleiteter Frühphasen-Investmentfonds, hat eine Milliarde Euro eingesammelt, um Gründer:innen zu unterstützen, auf die Europa setzt. Plurals Ziel ist es, Europa so stark zu prägen, dass sich dies auf das Bruttoinlandsprodukt auswirkt. Das Unternehmen unterstützt Gründer:innen, die das entwickeln, was eine sich wandelnde Welt im nächsten Jahrzehnt am dringendsten benötigt: Energie,...
-

Plural Raises €1bn to Back the Frontier Founders Building a New Europe

LONDON, TALLINN, Estonia & PARIS--(BUSINESS WIRE)--Plural, the early-stage investment fund led by founders and operators, has raised €1bn to back the founders Europe is counting on. Plural’s ambition is to have GDP-level impact on Europe. It backs founders building what a changing world needs most over the next decade: energy, AI infrastructure, defence, health and other frontier technologies. For two decades, the bulk of the world’s most valuable technology companies have been built in the US...
-

ViiV Healthcare’s Tivicay and Dovato receive positive CHMP opinion for young children living with HIV, advancing efforts to close paediatric treatment gaps in the EU

LONDON--(BUSINESS WIRE)--ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Shionogi as a shareholder, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the approval of Tivicay (dolutegravir [DTG]) and Dovato (dolutegravir/lamivudine [DTG/3TC]) to extend their use to eligible younger age groups. Globally around 50% of untreated infants living with HIV die by age two and only 55% of ch...
-

Plural lève €1 milliard pour soutenir les entrepreneurs de la deep tech qui bâtissent une nouvelle Europe

Londres, Tallinn et Paris--(BUSINESS WIRE)--Plural, le fonds d’investissement early-stage dirigé par d’anciens entrepreneurs et dirigeants d’entreprises, annonce avoir levé €1 millions d’euros pour soutenir les entrepreneurs sur lesquels repose l’avenir de l’Europe. L’ambition de Plural est d’avoir un impact sur l’Europe à l’échelle de son PIB. Le fonds soutient les entrepreneurs qui développent les technologies dont le monde aura le plus besoin au cours de la prochaine décennie : énergie, infr...
-

Syntis Bio Reports Late-Breaking SYNTIETY-1 Data at ObesityWeek® 2026 Demonstrating Daily Oral SYNT-101 Mimics Gastric Bypass Hormone Response with Placebo-Like Tolerability

BOSTON--(BUSINESS WIRE)--Syntis Bio, Inc., a clinical-stage biopharmaceutical company advancing novel oral therapeutics that uniquely leverage the small intestine, today announced that results from its Phase 1/1b SYNTIETY-1 trial of SYNT-101, an investigational once-daily tablet for obesity, in two posters, including a late-breaking presentation, were presented at The Obesity Society’s 44th Annual Meeting at ObesityWeek® 2026. Data from the trial demonstrated that SYNT-101 reproduced the meal-d...
-

Houlihan Lokey Further Expands Global Oil & Gas Group With Senior Hire in London

LONDON--(BUSINESS WIRE)--Houlihan Lokey, Inc. (NYSE:HLI), the global investment bank, today announced the appointment of Fahd Aijaz as a Managing Director in the Oil & Gas Group. Based in London, Mr. Aijaz will lead the firm’s industry coverage of European companies and investors, in collaboration with other senior partners across the global Oil & Gas Group. Mr. Aijaz brings a wealth of expertise in advising leading corporates and private capital investors, having advised on more than 5...
-

LEO Pharma Delivers 11% Revenue Growth at CER and Achieves Strategic Milestones

BALLERUP, Denmark--(BUSINESS WIRE)--LEO Pharma delivers 11% revenue growth at CER and achieves strategic milestones...